BCRX vs PTCT
BCRX: BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases using structure-guided drug design. PTCT: A commercial-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for rare genetic diseases.
Side-by-side fundamentals
| Metric | BCRX | PTCT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $8.98 | $68.01 | |
| Market cap as of 2026-08-03 | $2.3B | $5.7B | |
| PEG as of 2026-08-03 | -0.01 | 0.86 | BCRX lower |
| Net margin as of 2026-08-03 | -51.7% | -14.5% | PTCT higher |
| Gross margin as of 2026-08-03 | +97.8% | +73.2% | BCRX higher |
| Operating margin as of 2026-08-03 | -45.1% | -1.6% | PTCT higher |
| ROE as of 2026-08-03 | -328.8% | -351.9% | BCRX higher |
| ROA as of 2026-08-03 | -97.3% | -4.3% | PTCT higher |
| Debt / equity as of 2026-08-03 | 2.26 | 848.93 | BCRX lower |
| Revenue growth (YoY) as of 2026-08-03 | +75.9% | -53.3% | BCRX higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | +35.3% | PTCT higher |
| Beta as of 2026-08-03 | 0.74 | 0.98 | |
| 1-year return as of 2026-07-31 close | +10.3% | +30.5% | PTCT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.